Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421143 | 0.89 | AGTR2 (0.39) | AGTR2AGTR1ABCB11EGFRERBB2 | |
| SCHEMBL3974380 | 0.87 | AGTR2 (0.50) | AGTR2AGTR1ABCB11EGFRERBB2 | |
| SCHEMBL8419183 | 0.82 | ALOX15 (0.41) | AGTR2ALDH1A1 | |
| SCHEMBL9193450 | 0.82 | AGTR2 (0.51) | AGTR2AGTR1ABCB11EGFRERBB2 | |
| SCHEMBL906601 | 0.81 | AGTR2 (0.41) | AGTR2AGTR1ABCB11EGFRERBB2 | |
| SCHEMBL4373827 | 0.80 | ABCB11 (0.55) | AGTR2AGTR1ABCB11EGFRERBB2 | |
| SCHEMBL682490 | 0.80 | AGTR2 (0.54) | AGTR2AGTR1ABCB11EGFRERBB2 | |
| SCHEMBL9194556 | 0.80 | AGTR2 (0.52) | AGTR2AGTR1ABCB11EGFRERBB2 | |
| SCHEMBL9194756 | 0.80 | AGTR2 (0.52) | AGTR2AGTR1ABCB11EGFRERBB2 | |
| SCHEMBL683298 | 0.80 | AGTR2 (0.62) | AGTR2AGTR1ABCB11EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538133-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-06-16 | — | — | US | disclosed |
| US-6844443-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2005-01-18 | — | — | US | disclosed |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-03-04 | — | — | US | disclosed |
| US-6608210-B2 | Such as 1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-((2'-(1H-tetrazol-t-yl)biphenyl-4-yl)methyl) benzimidazol-7-carboxylate; exhibits antihypertensive activity and strong angiotensin II antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-0720982-B1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-10-17 | — | — | US | disclosed |
| US-6355808-B2 | ANGAGONIZING ANGIOTENSIN II | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | TAKEDA PHARAMCEUTICAL COMPANY, LIMITED (JP) | 2001-11-29 | — | — | US | disclosed |
| US-6232334-B1 | HAVE POTENT ANGIOTENSIN II ANTAGONISTIC ACTIVITY AND ANTIHYPERTENSIVE ACTIVITY, FOR TREATING CIRCULATORY SYSTEM DISEASES SUCH AS HYPERTENSIVE DISEASES, HEART DISEASES, STROKES, CEREBRAL APOPLEXY AND NEPHRITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6004989-A | ETHYL 2-ETHOXY-1-(2'-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL) BENZIMIDAZOLE-7-CARBOXYLATE AND SALTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-21 | — | — | US | disclosed |
| US-5962491-A | ANGIOTENSIN ANTAGONIST, HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, STROKES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5703110-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | MRM1, CARM1, H1-4 | AGTR2 2490/4885AGTR1 1906/4885ABCB11 1224/4885 |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, H1-4 | AGTR2 2919/4885AGTR1 2302/4885ABCB11 1312/4885 |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, NSD1 | AGTR2 2836/4885AGTR1 2191/4885ABCB11 1237/4885 |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | REN, AGTR1, H1-3 | AGTR2 11/4885AGTR1 2/4885ABCB11 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.